Meriofert

Luteinising Hormone (Human) and Follicle‑Stimulating Hormone, the active ingredients in Meriofert, are gonadotropins presented as a sterile injectable solution for intramuscular or subcutaneous use. They are employed to stimulate ovarian follicle development and induce ovulation in women with infertility due to anovulation.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to support ovarian stimulation and ovulation.

- Infertility due to anovulation: induces follicular development and ovulation. - Assisted reproductive technology (ART): provides hormonal support during IVF and ICSI cycles. - Controlled ovarian hyperstimulation: enhances the number of mature oocytes retrieved for fertilisation.

Adverse reactions may occur following administration of Meriofert.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Headache. - Nausea. - Transient dizziness. - Mild ovarian hyperstimulation syndrome (OHSS).

Serious or Rare Side Effects: - Severe OHSS with rapid weight gain and ascites. - Thromboembolic events. - Allergic reactions including rash, urticaria, or anaphylaxis. - Multiple pregnancy. - Ectopic pregnancy. - Severe abdominal pain or hemorrhage.

Prior assessment and monitoring are essential when using Meriofert. - Baseline ovarian assessment: evaluate follicular reserve before initiation. - Estradiol monitoring: check serum levels during stimulation. - Use lowest effective dose: minimise risk of OHSS. - Contraindication in known hypersensitivity: avoid if allergic to any component. - Pregnancy avoidance: do not use in confirmed pregnancy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications affecting ovarian response or coagulation.

Major Interactions (Avoid): - Concurrent high‑dose estrogen therapy: increases risk of severe OHSS. - Other gonadotropins administered simultaneously: may cause excessive ovarian stimulation. - GnRH agonists used for down‑regulation without proper timing: can blunt intended response.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for injection‑site bleeding. - Corticosteroids: may alter hormonal response, require dose adjustment. - Thyroid hormone replacement: assess thyroid status as it influences ovarian function.